The Pharmaceutical Market: Ireland

Publisher Name :
Date: 25-Apr-2013
No. of pages: 0
Inquire Before Buying


Ireland has experienced rapid economic growth over the past 20 years, and has invested in large scale renovation and redevelopment of its healthcare infrastructure. That said, the country is in the midst of a severe economic downturn, with GDP expected to contract in 2012. Due to the recession and Ireland's huge budget deficit, the country has received an 85 billion euro (US$113 billion) bailout from the EU and IMF. As a result, the government faces an extremely tight financial operating environment in the next few years. It has generally sought to protect healthcare, especially frontline services, from the kinds of cuts experienced elsewhere, but health is not unaffected. A progression of measures has been introduced as the economic position has worsened, most recently the Budget 2011 and related National Recovery Plan.

In March 2011, the government announced plans to introduce Universal Health Insurance (UHI) by 2016. Underpinning the UHI system will be the principle of access according to need and payment according to ability to pay. Insurance with a public or private insurer will be compulsory, with insurance payments related to ability to pay. The government is also planning to remove fees for GP care, which will be implemented in phases, firstly for claimants of free drugs under the Long-Term Illness scheme and the High-Tech Drugs scheme, before being extended to all. Under UHI, public hospitals will no longer be managed by the HSE. They will be independent, not-for-profit trusts with managers accountable to their boards. Hospitals will be paid according to the care they deliver and will be incentivised to deliver more care in a ‘money follows the patient' system. The government has also reiterated plans to introduce reference pricing and generic substitution, as cost saving measures.

Most global companies have some manufacturing presence in the pharmaceutical market in Ireland. Drugs are either produced in finished form for export, or exported on to other facilities for finishing. A number of branded drugs go off patent in 2012, including Pfizer's Lipitor and Eli Lilly's Zyprexa, which could have a negative impact on the industry. However, several multinational companies have been moving into the biologic sector in preparation for the loss of profit from these blockbuster drugs. While the multinational presence is very strong, Ireland has very few domestic producers. In September 2011, Alkermes completed its merger with Elan Drug Technologies (EDT) to form a new company, Alkermes Plc., which is headquartered in Dublin. In September 2011, Pfizer announced it was to invest US$200.0 million at its Grange Castle site, to add two processing suites and to expand current production and product testing capabilities. In September 2011, MSD opened its new R&D centre at its Ballydine site, creating 70 new jobs. Previously, in June 2011, MSD opened two new facilities at the site in Brinny.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

The Pharmaceutical Market: Ireland

Table Of Contents

  • Latvia Pharmaceuticals and Healthcare Report Q3 2012
    Published: 08-May-2012        Price: US 1295 Onwards        Pages: 80
    BMI View: We have revised downwards our 2012 projections for the growth of the Latvian pharmaceutical market on account of weaker growth towards the end of 2011, combined with ongoing concerns over the external economic environment in Europe, which will not be supportive of Latvian exports and therefore economic growth. We forecast 4.3% year-on-year (y-o-y) local currency growth in 2012, with the market expected to be valued at LVL296mn (US$540mn) by the end of the year. Risks are mostly to the ......
  • Nigeria Pharmaceuticals and Healthcare Report Q3 2012
    Published: 08-May-2012        Price: US 1295 Onwards        Pages: 101
    BMI View: The Nigerian pharmaceutical market continues to be seen as a risky proposition to multinationals. While the country’s oil revenues are significant, income distribution remains extremely uneven, resulting in per capita spending on medicines of under US$10 per annum, most of which is met through private funding. Affordability of pharmaceuticals has come under further pressure due to the January 2012 removal of fuel subsidies, which have resulted in higher inflation and increased produc......
  • Sweden Pharmaceuticals and Healthcare Report Q3 2012
    Published: 08-May-2012        Price: US 1295 Onwards        Pages: 72
    BMI View: Our five-year forecasts for the Swedish pharmaceutical market show a decline in its overall size, which is expected to fall to SEK42.02bn (US$5.64bn) by 2016. Key reasons for this pessimism include patent expirations and the subsequent entry of copy products, coupled with the government’s focus on cost containment through measures that will encourage the consumption of cheaper generic medicines. Nevertheless, population ageing as well as continued growth will continue to promote the ......
  • Tanzania Pharmaceuticals and Healthcare Report Q3 2012
    Published: 08-May-2012        Price: US 1295 Onwards        Pages: 43
    BMI View: It is vital the Tanzanian government assesses its medicine procurement systems. The expiry of medicines does not bode well for the state and its high reliance on donor funding for the healthcare sector, particularly as reports have highlighted the poor availability of essential medicines in the country. Furthermore, we believe the investment in improving the medicine procurement process will increase Tanzania's attractiveness as a location in which to sell medicines. Headline Expendi......
  • Australia Pharmaceuticals and Healthcare Report Q3 2012
    Published: 08-May-2012        Price: US 1295 Onwards        Pages: 100
    BMI View: Given the country’s increasingly ageing population and the consequential rise in noncommunicable diseases, Australia is a highly attractive place for multinational companies despite lower growth potential compared to emerging markets. However, we caution that the government’s funding of the Pharmaceutical Benefits Scheme (PBS) may be unsustainable, compounded by a lacklustre economic growth that may pose threats to the pharmaceutical industry if the government were to pursue aggres......
  • Turkey Pharmaceuticals and Healthcare Report Q3 2012
    Published: 15-May-2012        Price: US 1295 Onwards        Pages: 102
    BMI View: Before 2010, Turkey's pharmaceutical market growth was rapidly driven by modernisation, growing investment and improving awareness about healthcare. Since 2009, Turkey's pharmaceutical industry has been beset by government-imposed price controls and the worsening economic environment has moderated some of the more optimistic outlooks for this market. The drug market in 2012 will be defined by the price cutting and public discount decree announced in November 2011, though we note the mo......
  • Bangladesh Pharmaceuticals and Healthcare Report Q4 2012
    Published: 10-Oct-2012        Price: US 1295 Onwards        Pages: 91
    BMI View: While geographic diversification and investment into the pharmaceutical and healthcare sector of emerging economies, such as Bangladesh, may be a favourable strategy for any multinational pharmaceutical company - it is vital that a company recognises both the rewards and the risks present in a market. With regards to assessing risks in the Bangladeshi healthcare sector, we have identified those emanating from the state's political/economic profile (such as high inflation) and indus......
  • Estonia Pharmaceuticals and Healthcare Report Q4 2012
    Published: 10-Oct-2012        Price: US 1295 Onwards        Pages: 77
    BMI View: We continue to view Estonia as a low-potential market, largely on account of its small - and gradually declining - population. Short-term development of its pharmaceutical market will be shaped by the factors including prevailing economic conditions, patent expirations and government encouragement of the consumption of cheaper generic medicine. We expect imports to remain of crucial importance to market supply, with Estonia lacking a major domestic drug producer and with local rese......
  • West and Central Africa Pharmaceuticals and Healthcare Report Q4 2012
    Published: 10-Oct-2012        Price: US 1295 Onwards        Pages: 90
    BMI View: We hold to our view that Cameroon's medium-to-long-term drug market expansion potential remains highly dependent on the country's economic growth and is strongly linked to rising income and greater consumer purchasing power. We see Cameroon enjoying above-trend real GDP growth for the next several years as new oil production and a set of major new investments give a temporary boost to the economy. However, the government has limited funds to make the investment needed to improve th......
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs